A Double-blind, Placebo-controlled, Randomized, Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs Guselkumab (Primary)
- Indications Crohn's disease; Erythrodermic psoriasis; Familial adenomatous polyposis; Hidradenitis suppurativa; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 21 Jan 2019 Status changed from recruiting to completed.
- 08 Aug 2018 Status changed from not yet recruiting to recruiting.
- 28 May 2018 New trial record